Gonzalo Crespo

Gonzalo Crespo

Auto-generated profile, based on publicly available information

Gonzalo Crespo

Liver Unit, Hospital Clinic, IDIBAPS, Ciberehd, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2014 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
GCG. Crespo
G. Crespo
SLS. Lens
S. Lens
MGM. Gambato
M. Gambato
JCJosé A. Carrión
José A. Carrión
ZMZ. Mariño
Z. Mariño
XFX. Forns
X. Forns
The value of transient elastography (TE) to assess clinical outcomes in hepatitis C recurrence after liver transplantation (LT) has not been explored so far. We studied 144 hepatitis C–infected and 48 non–hepatitis C virus (HCV)‐infected LT recipients and evaluated the prognostic value of TE 1 year after transplantation to predict clinical decompensations and graft and patient survival. In HCV patients, cumulative probabilities of liver decompensation 5 years after LT were 8% for patients with liver stiffness measurement (LSM) <8.7 kilopascals (kPa) versus 47% for patients with LSM ≥ 8.7 kPa (p < 0.001). Five‐year graft and patient cumulative survival were 90% and 92% in patients with LSM < 8.7 kPa (p < 0.001) and 63% and 64% in patients with LSM ≥ 8.7 kPa, respectively (p < 0.001). Patients with low LSM 1 year after LT had excellent outcomes independently from receiving antiviral treatment or achieving sustained virological response (SVR). In contrast, graft survival significantly improved in patients with LSM ≥ 8.7 kPa who achieved SVR. No association between outcomes and LSM at 12 months was observed in non‐HCV patients. In conclusion, LSM 1 year after LT is a valuable tool to predict hepatitis C‐related outcomes in recurrent hepatitis C and can be used in clinical practice to identify the best candidates for antiviral therapy.

1 October 2014 in Journal of Clinical Virology
Verified
Journal Article
Closed access
CFCarlos Fernández-Carrillo
Carlos Fernández-Carrillo
MCMairene Coto-Llerena
Mairene Coto-Llerena
PGPatricia González
Patricia González
GCGonzalo Crespo
Gonzalo Crespo
LMLaura Mensa
Laura Mensa
SPSofía Pérez-del-Pulgar
Sofía Pérez-del-Pulgar

1 April 2013 in Journal of Hepatology
Verified
Journal Article
Closed access
LMLaura Mensa
Laura Mensa
SPSofía Pérez-del-Pulgar
Sofía Pérez-del-Pulgar
GCGonzalo Crespo
Gonzalo Crespo
GKGeorge Koutsoudakis
George Koutsoudakis
CFCarlos Fernández-Carrillo
Carlos Fernández-Carrillo
XFXavier Forns
Xavier Forns

1 May 2012 in Gastroenterología y Hepatología
Verified
Journal Article
Closed access
GCGonzalo Crespo
Gonzalo Crespo
SLSabela Lens
Sabela Lens

1 May 2017 in Transplantation
Verified
Journal Article
Closed access
CFCarlos Fernández-Carrillo
Carlos Fernández-Carrillo
GCGonzalo Crespo
Gonzalo Crespo
JRJuan de la Revilla
Juan de la Revilla
LCLluís Castells
Lluís Castells
MBMaria Buti
Maria Buti
MLMaria Carlota Londono
Maria Carlota Londono
Background Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated for HCV before liver transplant (LT) to eliminate the virus before surgery. However, the unpredictability of donor organ availability may limit treatment duration. Interruption of HCV treatment with resumption post-LT is 1 potential solution which has not been investigated widely. Methods Patients from 5 clinical centers included in the large, national, noninterventional Hepa-C registry who started treatment with direct-acting antiviral agents while awaiting LT were identified retrospectively and followed up prospectively. Fifteen patients who had treatment interruptions around LT were identified. Results The majority of patients (12/15) received interferon-free regimens, most commonly sofosbuvir + daclatasvir (8/12), for a total of 24 weeks (13/15). Treatment was discontinued temporarily for a median of 5 (range, 2-33) days. Fourteen patients completing 12 weeks of follow-up achieved a sustained virological response. One patient who died before week 12 posttreatment achieved a response at posttreatment week 4. Treatment was generally well tolerated. Serious adverse events were recorded in 2 of 15 patients (anaemia in 1 patient; pneumonia in 1 patient); all arose after LT. Conclusions Resumption of direct-acting antiviral agent therapy after a temporary interruption around LT was highly effective, achieving sustained virological response in all patients who completed 12 weeks of posttreatment follow-up. Treatment was generally well tolerated pretransplantation and posttransplantation, with a low rate of serious adverse events. Such a strategy may offer an important new approach to the treatment of patients awaiting LT which may be assessed in future studies.

1 April 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
KCKarina Chavez
Karina Chavez
AMAngela Mendez-Bocanegra
Angela Mendez-Bocanegra
ASAlejandro Fernandez Simon
Alejandro Fernandez Simon
OSOriol Sendino
Oriol Sendino
CMCristina Rodriguez de Miguel
Cristina Rodriguez de Miguel
ACAndres Cardenas
Andres Cardenas